Wedbush Brokers Boost Earnings Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities research analysts at Wedbush upped their Q3 2025 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals in a report issued on Wednesday, April 24th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.32) per share for the quarter, up from their prior forecast of ($0.33). Wedbush has a “Outperform” rating and a $33.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($1.40) EPS.

A number of other equities research analysts have also recently issued reports on DAWN. Piper Sandler reiterated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. The Goldman Sachs Group cut their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday. Finally, Needham & Company LLC lifted their price objective on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Day One Biopharmaceuticals Stock Performance

DAWN stock opened at $14.92 on Friday. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -6.27 and a beta of -1.48. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $17.85. The stock’s fifty day moving average is $15.22 and its two-hundred day moving average is $13.81.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total transaction of $322,200.00. Following the transaction, the insider now directly owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the transaction, the insider now owns 1,224,662 shares of the company’s stock, valued at approximately $19,729,304.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the transaction, the insider now directly owns 1,174,662 shares in the company, valued at approximately $18,818,085.24. The disclosure for this sale can be found here. Insiders have sold a total of 55,781 shares of company stock valued at $883,160 over the last three months. Company insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently made changes to their positions in DAWN. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Day One Biopharmaceuticals by 130.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $29,000. Quintet Private Bank Europe S.A. lifted its holdings in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after buying an additional 1,000 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after buying an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Day One Biopharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after buying an additional 2,554 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.